TY - JOUR
T1 - Radiation Therapy for Rectal Cancer
T2 - Executive Summary of an ASTRO Clinical Practice Guideline
AU - Wo, Jennifer Y.
AU - Anker, Christopher J.
AU - Ashman, Jonathan B.
AU - Bhadkamkar, Nishin A.
AU - Bradfield, Lisa
AU - Chang, Daniel T.
AU - Dorth, Jennifer
AU - Garcia-Aguilar, Julio
AU - Goff, David
AU - Jacqmin, Dustin
AU - Kelly, Patrick
AU - Newman, Neil B.
AU - Olsen, Jeffrey
AU - Raldow, Ann C.
AU - Ruiz-Garcia, Erika
AU - Stitzenberg, Karyn B.
AU - Thomas, Charles R.
AU - Wu, Q. Jackie
AU - Das, Prajnan
N1 - Funding Information:
Sources of support: This work was funded by the American Society for Radiation Oncology .
Funding Information:
Sources of support: This work was funded by the American Society for Radiation Oncology. Christopher Anker: International Journal of Radiation Oncology, Biology, and Physics (associate senior editor), Lake Champlain Cancer Research Organization and J. Walter Juckett Cancer Research Foundation (research grant), National Cancer Institute (NCI) Rectal-Anal Task Force (member); Northern New England Clinical Oncology Society (research grants, honoraria, travel expenses), Susan G. Komen Foundation (research grant), Syntactx (honoraria?data safety monitoring board for pancreatic cancer trial); Daniel Chang: Varian (research grants honoraria, travel expenses), ViewRay (stock); Prajnan Das (chair): American Society for Radiation Oncology, MD Anderson Cancer Center Madrid, NCI/Leidos (honoraria), NCI Rectal-Anal Task Force vice chair; Dustin Jacqmin: Asto CT, WePassed LLC (consultant, honoraria?initiated June 2020 during final approval); Patrick Kelly: ViewRay (research grant); Jeffrey Olsen: International Journal of Radiation Oncology, Biology, and Physics (associate editor); Syntactx Clinical Events Committee chair (initiated April 2020, after draft development); Ann Raldow: Clarity PSO/RO-ILS Radiation Oncology Healthcare Advisory Board (consultant, honoraria), Intelligent Automation (consultant), ViewRay (research grant); Karyn Stitzenberg (Society of Surgical Oncology representative): Johnson and Johnson, Merck, Pfizer, Myriad Genetics, United Healthcare, Vertex Pharmaceuticals, Mygen (all stocks); Q. Jackie Wu: NIH/NCI, Varian (research grants). Jonathan Ashman, Nishin Bhadkamkar (American Society for Clinical Oncology representative), Lisa Bradfield, Jennifer Dorth, Julio Garcia-Aguilar (Society of Surgical Oncology representative), David Goff (patient representative), Neil Newman, Erika Ruiz-Garcia (American Society for Clinical Oncology representative), Charles Thomas, and Jennifer Wo (Vice-Chair) reported no disclosures.
Publisher Copyright:
© 2020 American Society for Radiation Oncology
PY - 2021/1/1
Y1 - 2021/1/1
N2 - Purpose: This guideline reviews the evidence and provides recommendations for the indications and appropriate technique and dose of neoadjuvant radiation therapy (RT) in the treatment of localized rectal cancer. Methods: The American Society for Radiation Oncology convened a task force to address 4 key questions focused on the use of RT in preoperative management of operable rectal cancer. These questions included the indications for neoadjuvant RT, identification of appropriate neoadjuvant regimens, indications for consideration of a nonoperative or local excision approach after chemoradiation, and appropriate treatment volumes and techniques. Recommendations were based on a systematic literature review and created using a predefined consensus-building methodology and system for grading evidence quality and recommendation strength. Results: Neoadjuvant RT is recommended for patients with stage II-III rectal cancer, with either conventional fractionation with concurrent 5-FU or capecitabine or short-course RT. RT should be performed preoperatively rather than postoperatively. Omission of preoperative RT is conditionally recommended in selected patients with lower risk of locoregional recurrence. Addition of chemotherapy before or after chemoradiation or after short-course RT is conditionally recommended. Nonoperative management is conditionally recommended if a clinical complete response is achieved after neoadjuvant treatment in selected patients. Inclusion of the rectum and mesorectal, presacral, internal iliac, and obturator nodes in the clinical treatment volume is recommended. In addition, inclusion of external iliac nodes is conditionally recommended in patients with tumors invading an anterior organ or structure, and inclusion of inguinal and external iliac nodes is conditionally recommended in patients with tumors involving the anal canal. Conclusions: Based on currently published data, the American Society for Radiation Oncology task force has proposed evidence-based recommendations regarding the use of RT for rectal cancer. Future studies will look to further personalize treatment recommendations to optimize treatment outcomes and quality of life.
AB - Purpose: This guideline reviews the evidence and provides recommendations for the indications and appropriate technique and dose of neoadjuvant radiation therapy (RT) in the treatment of localized rectal cancer. Methods: The American Society for Radiation Oncology convened a task force to address 4 key questions focused on the use of RT in preoperative management of operable rectal cancer. These questions included the indications for neoadjuvant RT, identification of appropriate neoadjuvant regimens, indications for consideration of a nonoperative or local excision approach after chemoradiation, and appropriate treatment volumes and techniques. Recommendations were based on a systematic literature review and created using a predefined consensus-building methodology and system for grading evidence quality and recommendation strength. Results: Neoadjuvant RT is recommended for patients with stage II-III rectal cancer, with either conventional fractionation with concurrent 5-FU or capecitabine or short-course RT. RT should be performed preoperatively rather than postoperatively. Omission of preoperative RT is conditionally recommended in selected patients with lower risk of locoregional recurrence. Addition of chemotherapy before or after chemoradiation or after short-course RT is conditionally recommended. Nonoperative management is conditionally recommended if a clinical complete response is achieved after neoadjuvant treatment in selected patients. Inclusion of the rectum and mesorectal, presacral, internal iliac, and obturator nodes in the clinical treatment volume is recommended. In addition, inclusion of external iliac nodes is conditionally recommended in patients with tumors invading an anterior organ or structure, and inclusion of inguinal and external iliac nodes is conditionally recommended in patients with tumors involving the anal canal. Conclusions: Based on currently published data, the American Society for Radiation Oncology task force has proposed evidence-based recommendations regarding the use of RT for rectal cancer. Future studies will look to further personalize treatment recommendations to optimize treatment outcomes and quality of life.
UR - http://www.scopus.com/inward/record.url?scp=85096023518&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096023518&partnerID=8YFLogxK
U2 - 10.1016/j.prro.2020.08.004
DO - 10.1016/j.prro.2020.08.004
M3 - Article
C2 - 33097436
AN - SCOPUS:85096023518
SN - 1879-8500
VL - 11
SP - 13
EP - 25
JO - Practical Radiation Oncology
JF - Practical Radiation Oncology
IS - 1
ER -